LANGHORNE, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter ended September 30, 2023, after the market closes on November 13, 2023.
Following the release of its financial and operating results, the Company will host a conference call at 4:30 P.M. ET on November 13, 2023. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portion of NEXGEL’s Investor Relations website. The webcast will be archived for approximately 90 days.
NEXGEL Third Quarter 2023 Financial Results Conference Call
Date: November 13, 2023
Time: 4:30 P.M. ET
Live Call: + 1-877-407-9208 (U.S. Toll Free) or + 1-201-493-6784 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1640412&tp_key=d1c55ca731
For interested individuals unable to join the conference call, a replay will be available through November 27, 2023, at + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13742264. An archived version of the webcast will also be available on NEXGEL’s Investor Relations site: https://ir.nexgel.com/.
About NEXGEL, INC.
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.74 |
| Daily Change: | 0.08 1.72 |
| Daily Volume: | 24,517 |
| Market Cap: | US$32.180M |
November 13, 2024 November 11, 2024 October 10, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
